Related Experiment Videos
C-reactive protein, inflammation, and coronary risk
1Division of Cardiovascular Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
The Medical Clinics of North America
|February 24, 2000
Summary
High-sensitivity C-reactive protein (hs-CRP) levels interact with common preventive therapies. Measuring hs-CRP may help target cardiovascular risk reduction strategies effectively.
Area of Science:
- Cardiovascular Medicine
- Biomarkers
- Preventive Cardiology
Background:
- Elevated high-sensitivity C-reactive protein (hs-CRP) is linked to increased cardiovascular risk.
- Current cardiovascular risk assessment may not fully leverage inflammatory markers.
Purpose of the Study:
- To investigate the relationship between baseline hs-CRP concentrations and the efficacy of pharmacologic therapies.
- To explore the utility of inflammatory markers in tailoring preventive cardiovascular strategies.
Main Methods:
- Analysis of data on baseline hs-CRP levels.
- Evaluation of the effectiveness of standard pharmacologic treatments for cardiovascular prevention.
- Assessment of the potential role of hs-CRP in risk stratification.
Main Results:
- Baseline hs-CRP concentration influences the efficacy of common preventive therapies.
- hs-CRP levels may indicate potential for risk modification through targeted interventions.
- Inflammatory markers show promise for enhancing cardiovascular risk assessment.
Conclusions:
- hs-CRP is a significant factor in the efficacy of cardiovascular preventive therapies.
- Targeting therapies based on hs-CRP levels could improve risk management.
- Inflammatory markers are valuable additions to routine cardiovascular risk assessment.